anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine composition for diminishing inflammation and relieving the sore throat and a preparation method thereof. The composition is prepared from roots or leaves of ilex asprella (hook. et arn.) champ. ex benth., all-grass of picria fel-terrae lour., radix isatidis and flos lonicerae. The invention further provides the preparation method of the traditional Chinese medicine composition for diminishing inflammation and relieving the sore throat.
Every participating site will select 50 cases of pregnant women who underwent cervical ripening by Dilapan-S prior to induction of labor. These cases has to fulfill inclusion/exclusion criteria defined in the protocol.
Ambulatory patient wearable vital sign monitoring system, often comprising a plurality of ambulatory patient wearable ECG sensors, pulse oximeters, and oscillometric blood pressure monitors, configured to transmit sensor data to a wearable computerized device such as a smartphone. The smartphone will typically be configured to obtain the patient's health history and other health status information, often by querying the patient. The device will use this health history and health status information to select vital sign operating times and sensor data acquisition parameters. The system may also use the history, health status information and the sensor data to return diagnostic information pertaining to the patient's history the patient and optionally other devices or caregivers. In some embodiments, the system may also report on medication adherence as well. Examples of multi-sensor neck worn devices, three-sensor hand carried devices, and purely ear worn devices (e.g. for sleep apnea) are presented.
We present a case study of a young male with a history of 22q11.2 deletion syndrome (22qDS), diagnosed with systemic capillary leak syndrome (SCLS) who presented with acute onset of diffuse anasarca and sub-comatose obtundation. We hypothesized that his co-presentation of neurological sequelae might be due to blood-brain barrier (BBB) susceptibility conferred by the 22q11.2 deletion, a phenotype that we have previously identified in 22qDS. Using pre- and post-intravenous immunoglobulins (IVIG) patient serum, we studied circulating biomarkers of inflammation and assessed the potential susceptibility of the 22qDS BBB. We employed in vitro cultures of differentiated BBB-like endothelial cells derived from a 22qDS patient and a healthy control. We found evidence of peripheral inflammation and increased serum lipopolysaccharide (LPS) alongside endothelial cells in circulation. We report that the patient's serum significantly impairs barrier function of the 22qDS BBB compared to control. Only two other cases of pediatric SCLS with neurologic symptoms have been reported, and genetic risk factors have been suggested in both instances. As the third case to be reported, our findings are consistent with the hypothesis that genetic susceptibility of the BBB conferred by genes such as claudin-5 deleted in the 22q11.2 region promoted neurologic involvement during SCLS in this patient.
PURPOSE OF REVIEW: Dysfunction and thrombosis of mechanical heart valves, although uncommon, represents a challenge that requires multidisciplinary expertise for diagnosis and management. The aim of this review is to summarize strengths and weaknesses of diagnostic methods and therapeutic strategies for this uncommon but potentially life-threatening pathology.
RECENT FINDINGS: Expeditious diagnosis of mechanical valve thrombosis and exclusion of other diagnostic considerations, often with incorporation of multimodality imaging, can inform the best treatment strategy. Presentation of mechanical valve thrombosis can be asymptomatic or can include heart failure, life-threatening embolic events, or cardiogenic shock. Echocardiography, fluoroscopy and computed tomography are important in the evaluation of mechanical valve dysfunction. Therapeutic strategies for thrombosis include anticoagulation, systemic thrombolysis, and surgery. Choice of treatment depends on multiple factors including thrombus size, degree of valve dysfunction, clinical presentation, and available surgical expertise.
The antihypertensive effectiveness of nebivolol tablets as monotherapy has been demonstrated in three randomized, double-blind, multi-center, placebo-controlled trials at doses ranging from 1.25 to 40 mg for 12 weeks (Studies 1, 2, and 3). A fourth placebo-controlled trial demonstrated additional antihypertensive effects of nebivolol tablets at doses ranging from 5 to 20 mg when administered concomitantly with up to two other antihypertensive agents (ACE inhibitors, angiotensin II receptor antagonists, and thiazide diuretics) in patients with inadequate blood pressure control. 

The three monotherapy trials included a total of 2016 patients (1811 nebivolol tablets, 205 placebo) with mild to moderate hypertension who had baseline diastolic blood pressures (DBP) of 95 to 109 mmHg. Patients received either nebivolol tablets or placebo once daily for twelve weeks. Two of these monotherapy trials (Studies 1 and 2) studied 1716 patients in the general hypertensive population with a mean age of 54 years, 55% males, 26% non-Caucasians, 7% diabetics and 6% genotyped as PMs. The third monotherapy trial (Study 3) studied 300 Black patients with a mean age of 51 years, 45% males, 14% diabetics, and 3% as PMs.

Placebo-subtracted blood pressure reductions by dose for each study are presented in Table 2. Most studies showed increasing response to doses above 5 mg. 

Table 2. Placebo-Subtracted Least-Square Mean Reductions in Trough Sitting Systolic/Diastolic Blood Pressure (SiSBP/SiDBP mmHg) by Dose in Studies with Once Daily Nebivolol Tablets

Study 4 enrolled 669 patients with a mean age of 54 years, 55% males, 54% Caucasians, 29% Blacks, 15% Hispanics, 1% Asians, 14% diabetics, and 5% PMs. Nebivolol tablets, 5 mg to 20 mg, administered once daily concomitantly with stable doses of up to two other antihypertensive agents (ACE inhibitors, angiotensin II receptor antagonists, and thiazide diuretics) resulted in significant additional antihypertensive effects over placebo compared to baseline blood pressure. 

Effectiveness was similar in subgroups analyzed by age and sex. Effectiveness was established in Blacks, but as monotherapy the magnitude of effect was somewhat less than in Caucasians. 

The blood pressure lowering effect of nebivolol tablets was seen within two weeks of treatment and was maintained over the 24-hour dosing interval. 

There are no trials of nebivolol tablets demonstrating reductions in cardiovascular risk in patients with hypertension, but at least one pharmacologically similar drug has demonstrated such benefits.
PROBLEM TO BE SOLVED: To provide a method for treatment of skeletal disturbance and immune disorder by adjusting MDL-1 activity.SOLUTION: This is a method for adjusting bone resorption in a subject, based on such a finding that an action antagonizing MDL-1 activity has controlled bone invasion and inflammation. This method includes the administration to the subject of an effective amount of an antibody or its fragment specifically linking with MDL-1. In one embodiment, the antibody is a humanized one, purely human one, or chimera. The antibody fragment is Fab, Fab2 or Fv one. The antibody or the antibody fragment can conjugate other chemical moieties containing polyethylene glycol (PEG). The antibody or the antibody fragment controls also the bone resorption caused by inflammation. In addition, the antibody or the antibody fragment can control also the formation or activation of an osteoclast.
The invention relates to application of HyG in reducing MIC of imipenem high-drug-resistance pseudomonas aeruginosa, and the application proves that galloylhyperin can reduce the minimum inhibitory concentration of imipenem to high-drug-resistance pseudomonas aeruginosa through a growth curve experiment, a sterilization curve experiment and a drug sensitivity experiment. Galloyl hyperoside reduced the MIC of imipenem against highly resistant Pseudomonas aeruginosa from 4096. Mu.g/mL to 1024. Mu.g/mL at a concentration of 8. Mu.g/mL. The galloyl hyperin can be used as an auxiliary agent for inhibiting the growth of high-drug-resistance pseudomonas aeruginosa by imipenem, or used for preparing a high-drug-resistance pseudomonas aeruginosa growth inhibiting drug or a high-drug-resistance pseudomonas aeruginosa resisting drug, can be used as a targeted antibacterial drug and is used for inhibiting the growth of the high-drug-resistance pseudomonas aeruginosa; has important significance for the research and development of medicaments.
Epigenetics is an emerging field of research because of its involvement in susceptibility to diseases and aging. Hypoxia and hyperoxia are known to be involved widely in various pathophysiologies. Here, we compared the differential epigene expression pattern between Pleurodeles waltl and Mus musculus (commonly known as Iberian ribbed newt and mouse, respectively) exposed to hypoxia and hyperoxia. Adult healthy newts and mice were exposed to normobaric hypoxia (8% O2) and hyperoxia (80% O2) for 2 hours. We collected the lungs and analyzed the expression of hypoxia-inducible factor 1 alpha (Hif1α) and several key epigenes from DNA methyltransferase (DNMT) family, histone deacetylase (HDAC) family, and methyl-CpG binding domain (MBD) family. The exposure to hypoxia significantly increased the mRNA levels of DNA methyltransferase 3 alpha (Dnmt3α), methyl-CpG binding domain protein 2 (Mbd2), Mbd3, and histone deacetylase 2 (Hdac2) in lungs of newts, but decreased the mRNA levels of DNA methyltransferase 1 (Dnmt1) and Dnmt3α in lungs of mice. The exposure to hyperoxia did not significantly change the expression of any gene in either newts or mice. The differential epigene expression pattern in response to hypoxia between newts and mice may provide novel insights into the prevention and treatment of disorders developed due to hypoxia exposure.
PBMT will be delivered at 32-40 watts (W) (depending on participant skin pigmentation). PBMT will be applied to the quadriceps area. A study team member will use the quadriceps measurements of the treatment area to calculate the PBMT treatment time (approximately 5-20 minutes) and specified J/cm2. PBMT treatment will be provided 3 times per week, for 3 weeks.
It is planned to design 11 dose groups within 62.5 mg \~ 4000 mg for single-dose tolerability study. A single-center, randomized, blinded, placebo-controlled, dose escalation trial design is adopted. There are 8 subjects each in 62.5 mg, 125 mg, 3000 mg and 4000 mg dose groups, and 10 subjects each in other groups. Each group consists of half males and half females, including 2 placebo-controlled subjects (1 male and 1 female). The trial is carried out from low-dose group to high-dose group. Each subject only receives one dose of test drug, which is dissolved in 100 mL of 0.9% NS, intravenous drip. During the trial, the adverse events of subjects should be closely followed. The next dose group can be studied only when the observation of the previous dose group is completed and it is confirmed that the drug is safely tolerated. The test should be stopped in case of serious adverse reactions, or when more subjects experience adverse reactions and have reached termination criteria of the trial, even if the maximum dose has not been reached.

In order to investigate possible effect of infusion rate on the tolerability and to ensure the safety of subjects, the infusion time is planned to be 30 min in 62.5 mg, 125 mg and 250 mg low-dose groups; two infusion time, 30 min and 60 min, in 500 mg, 1000 mg and 2000 mg groups. Under the circumstance that subjects can tolerate 60-min infusion, the same dose group at infusion time of 30 min is added to investigate the possible effect of infusion rate on the tolerability. The 3000 mg and 4000 mg dose groups only receive 60-min infusion for investigation of tolerability.
An agent for treating atopy and a method for preparing the same are provided to obtain a therapeutic agent of the atopy from natural ingredients extracted from medicinal herbs without any chemical treatment, thereby being effectively used by everybody to treat the atopy without any side effects. An agent for treating atopy comprises an extract of plants, wherein the plants are roots of Rumex crispus, Ulmi cortex, Rehmannia glutinosa, Angelicae Gigantis Radix, and Perilla frutescens var. japonica Hara. A method for preparing the agent for treating atopy comprises the steps of: (a) preparing roots of Rumex crispus, Ulmi cortex, Rehmannia glutinosa, Angelicae Gigantis Radix, and Perilla frutescens var. japonica Hara; (b) obtaining an extract of the Ulmi cortex; (c) respectively obtaining an extract from the roots of Rumex crispus, Rehmannia glutinosa, Angelicae Gigantis Radix, and Perilla frutescens var. japonica Hara; and (d) mixing the extracts with water.
BACKGROUND: We reviewed the literature to examine if the thickness of the sinus membrane is a risk factor for perforation during lateral sinus lift surgery.
MATERIAL AND METHODS: We searched Embase, PubMed, and Web of Science databases till 4th December 2023 for studies examining the risk of perforation with different sinus membrane thicknesses. Studies reporting sinus membrane thickness in perforation and non-perforation cases were also included.
RESULTS: Eleven studies were eligible. All studies used cone beam computed tomography for measuring sinus membrane thickness. Meta-analysis showed that sinus membrane thickness was significantly lower in perforation cases as compared to non-perforation cases (MD: -0.91 95% CI: -1.48, -0.33 I2=94%). Four studies used 2mm as the cut-off to define thick and thin sinus membranes. Pooled analysis failed to demonstrate any significant difference in perforation rates (OR: 0.97 95% CI: 0.44, 2.17 I2=56%). Meta-analysis of studies using 1.5mm (OR: 0.66 95% CI: 0.29, 1.48 I2=72%) and 1mm cut-off (OR: 0.93 95% CI: 0.34, 2.56) also demonstrated similar non-significant results.
CONCLUSIONS: Our study shows that the sinus membrane is significantly thinner in cases with perforations as compared to those with no perforations. However, a meta-analysis based on different membrane thickness cut-offs failed to demonstrate a relationship between thinner sinus membranes and a higher risk of perforation. There is a need for further studies examining the role of sinus membrane thickness on perforation rates.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to N-derivatives of quinoline of the formula (I)   (symbols are given in p.1 of the formula). Synthesized compounds show inhibiting activity with respect to receptors for angiotensin-II and can be used for production of drugs. The latter can be used for treatment of patients with memory disorder and cognitive function, anxiety state at depression, senile feeble-mindedness and Alzheimer's disease. EFFECT: improved methods of synthesis, enhanced effectiveness of compounds. 15 cl, 7 tbl, 147 ex
The participants in the control group will be received advice on the standardised Malaysian food pyramid and be instructed to follow their usual standard care as suggested by their healthcare provider. Postpartum women in Malaysia typically attend postpartum healthcare visits with an exam on day 30 after childbirth but receive no other routine care following this appointment unless a specific health problem has been identified. Participants in the control group performed the same evaluations. They received the same incentives as those in the intervention group, but they did not receive any educational module and contact from the investigator during the 8 weeks follow-up.
<P>PROBLEM TO BE SOLVED: To prepare a warm sense-giving cosmetic which gives a sufficient warm sense, when brought into contact with the skin, has excellent temporal stability, and especially does not cause temporal discoloration, the expansion of a container, and the like.  <P>SOLUTION: This warm sense-giving cosmetic giving the warm sense, when brought into contact with the skin, and having creamy or gel-like viscosity is characterized by containing zeolite adjusted to a pH value of ≤10 and a polyethylene glycol containing polyethylene glycol liquid at the ordinary temperature and having an average mol. wt. of ≥1,200, containing the polyethylene glycol liquid at the ordinary temperature in an amount of ≥60 wt. % based on the total amount of the cosmetic, and substantially not containing water and a polyhydric alcohol except the polyethylene glycol.  <P>COPYRIGHT: (C)2004,JPO
Patients with moderate-severe pain will be approached with approval of nursing staff and front line nurse manager who determine their appropriateness for a trial of virtual reality (VR) exposure for up to 30 minutes. The trial and use of VR will be explained after meeting the inclusion criteria and they will be asked about their level of interest in trying the VR headset. If interested, the subject will indicate their verbal consent to proceed with the VR trial. They will be asked about any baseline discomforts of pain, anxiety/stress or other discomfort; which will be rated on a 0-10 numeric (visual analog) scale. A baseline heart rate will be recorded in beats per minute. The headset will be applied and adjusted for comfort, then the app will be started along with a timer to track the duration of their use up to a maximum of 30 minutes. When the Headset is removed, the duration of use will be noted. The change in post-exposure heart rate (in beats per minute) and discomforts of pain, anxiety/stress or other discomforts (subtracting baseline from 5 minute post-exposure data) will be recorded. Subjects will be asked about the ease of use, whether or not they would use VR again, and for any other comments they would like to express. The headset will be disinfected between patient use.
Medicaments contain (A) a pharmaceutically effective amount of human pepsin and/or human leukocyte pepsin-like enzyme (LPLE) and (B) a pharmaceutically acceptable carrier. The human pepsin used (pref. obtd. from human stomachs or urine) pref. has a molecular wt. of 32,000-38,000, an isoelectric point of 1-3 and a maximal absorption of 274nm, gives a positive ninhydrin reaction, and is readily soluble in water and insoluble in ether and chloroform. LPLE pref. has a molecular wt. of 35000-41000, an isoelectric point of 2.5-3.5 and a maximal absorption of 278 nm, gives a positive ninhydrin reaction, and is readily soluble in water and poorly soluble in ether and chloroform. Used in potentiation of phagocytolytic activity in the treatment of infectious diseases due to viruses, bacteria, eumycetes etc., as well as of gout, arteriosclerosis etc..
The study population included nonsplenectomized primary ITP inpatients 18 years of age or older. Patients who had a diagnosis of connective tissue disease, cancer (solid tumor or leukemia), or primary immune deficiency were excluded.
The role of the bronchoalveolar lavage fluid (BALF) microbiome in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) remains unclear. The advent of the metagenomic next-generation sequencing (mNGS) has made it possible to reveal the complex microbiome composition of the respiratory tract. This study aimed to explore whether there are differences in the BALF microbiome of AECOPD patients with different lung functions. We enrolled 55 AECOPD patients and divided them into a mild group (n = 31) and a severe group (n = 24) according to their lung function. We collected BALF and submitted it to mNGS and bioinformatics analysis. At the species level, mNGS identified 264 bacteria, 13 fungi and 12 viruses in the mild group, and 174 bacteria, 6 fungi and 6 viruses in the severe group. Mixed bacterial and viral infection occurred in both groups. At the genus level, Rothia and Veillonella were more abundant in the mild group, while Pseudomonas and Staphylococcus were more abundant in the severe group. At the species level, compared with the mild group, the relative abundance of Haemophilus influenzae and Pseudomonas aeruginosa was increased in the severe group. Besides, the BALF microbiome composition was similar between the two groups, and there was no significant difference in α and β diversity. Forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) (%) showed no significant correlation with the Shannon or Simpson index. The microbiome abundance was different between the mild and severe groups; however, microbiome diversity was similar between the two groups. Based on our findings, Haemophilus influenzae and Pseudomonas aeruginosa may be the pathogenic bacteria that cause the difference in lung function in patients with AECOPD.
FIELD: medicine. SUBSTANCE: method involves applying heparin to the belly skin in the uterus projection area containing Lyoton-1000 preparation. Abdominal decompression is concurrently applied for 30 min. Air rarefaction in the decompression chamber is selected in individual mode based on patient sensation but not greater than 50 mm Hg column. A patient has to feel light painless anterior abdominal wall drawing-in. EFFECT: adjusted blood microcirculation in cases when heparin electrophoresis is contraindicated. 3 tbl
All infants fulfilling the inclusion criteria during the 12 months recruitment window will potentially be enrolled in this randomized controlled trial of LISA premedication. Written informed consent will be acquired from parents or legal guardians. After the consent, infants needing the LISA will receive premedication as follows: caffeine citrate according to the clinical routine at study site, and randomly, either ketamine or sublingual glucose 30%. This study is a pilot study and 60 patients that will be randomized 1:1. Ketamine will be given in slow intravenous injection over 60 seconds. Glucose 30% will be given sublingually in the volume of 1 mL. After two minutes (from the end of administration of the study drug or reference drug), laryngoscopy will be started. To assess the effectiveness of both types of sedation, patients will be assessed using two pain assessment scales - the COMFORT scale and the FANS scale. 10 minutes before the procedure, the first assessment in the COMFORT and FANS scales will take place. The next assessment on both scales will take place during the procedure.